Citigroup To $47? Plus This Analysts Predicts $95 For Papa John’s
Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading.
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $65
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $62 to $65.
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers
FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023.
SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $60
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $65 to $60.
Rocket Pharmaceuticals Announces Updates From Phase 1 Clinical Trial For RP-A501
— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein
Rocket Pharmaceuticals To Acquire Renovacor In All-Stock Transaction Valued At ~$2.60/Share
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here’s What You Need To Know
Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00.
Shares of Rocket Pharmaceuticals are trading up 2.46% over the last 24 hours, at $16.23 per share.